| A | B | C | |
|---|---|---|---|
| 1 | Main | ||
| 2 | Brand Name | GSK1120212 | |
| 3 | Indication | Metastatic Melanoma BRAF V600 mutation | |
| 4 | Timeline | http://www.gsk.com/media/pressreleases/2011/2011_pressrelease_10018.htm | |
| 5 | Mechanism | MEK inhibitor | |
| 6 | Clinical Trials | ||
| 7 | Phase III "METRIC" GSK212 versus DTC/paclitaxel |